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1. Introduction
Sudden cardiac death (SCD) is defined by the death from unexpected circulatory arrest, usu‐
ally due to a cardiac arrhythmia occurring within one hour of the onset of symptoms [1].
It is a major health problem worldwide, with a prevalence estimated in the range of 300 000
to 350 000 cases per year in the United States [2]. Event rates in Europe are similar to those
in United States [3].
Coronary heart disease (CHD) is the leading cause of SCD explaining approximately 80% of
cases [4]; cardiomyopathies and primary electrical abnormalities account for most of the re‐
mainder. Approximately 50% to 70% of these deaths are related to ventricular tachyarrhyth‐
mias (ventricular fibrillation/ tachycardia) [5].
Available medical  therapies,  such as beta-blockers [6]  or anthiarrhytmic drugs including
amiodarone,  failed  to  abolish  the  occurrence  of  SCD after  a  myocardial  infarction  (MI)
[7], [8].
Implantable cardioverter defibrillators (ICD) are devices currently available capable of abort
life-threatening ventricular tachyarrhythmias and therefore prevent SCD.
Although  it  is  not  possible  to  prevent  all  cases  of  SCD  in  the  general  population,  the
main issue is the identification of individuals at increased risk that may benefit from ICD
implantation.
The highest risk of SCD in various heart diseases, either genetic or acquired, is related with
the previous occurrence of ventricular arrhythmias [9].In secondary prevention, predomi‐
nantly three randomized clinical trials have established the criteria for ICD implantation.
The antiarrhythmics versus Implantable Defibrillators (AVID) trial showed mortality reduc‐
tion with ICD among survivors of ventricular fibrillation or sustained ventricular tachycar‐
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dia causing severe symptoms [10]. The Canadian Implantable Defibrillator Study (CIDS)
trial showed a 20% relative risk reduction in mortality with ICD therapy compared to amio‐
darone [11], although not statistically significant. The Cardiac Arrest Study Hamburg
(CASH) trial confirm, though not with a statistical level of significance, the beneficial role of
ICD therapy in the treatment of cardiac arrest survivors during long-term follow-up [12].A
meta-analysis of these trials showed a 28% reduction in mortality due predominantly to a
reduction in arrhythmic death [13].
Thus,  patients  with ventricular  tachyarrhythmias (VT or  VF),  not  secondary to  a  transi‐
ent  or  reversible  cause,  meet  a  Class  I  indication for  ICD therapy.  In  addition,  patients
with syncope and significant  documented VT/VF also meet  indications  for  ICD therapy
(Level of Evidence A) [14].
However it is worth noting that, in most centers, the deployment of an ICD for primary pre‐
vention far exceeds the number of devices placed for secondary prevention.
Compared to optimal medical therapy, the use of ICDs in recent trials for primary prophy‐
laxis in CHD population was associated with a reduction in 5-year all-cause mortality of
23% to 36% and a reduction in absolute mortality of 1.5% to 3% per year.
2. Clinical parameters
Coronary disease is the main etiology of heart disease in Western countries and the major
cause of heart failure and SCD.It is defined by the presence of significant coronary stenosis
in a main coronary vessel or by the demonstration of previous MI.
Sudden death associated with CHD may occur in the acute context or months to years after
MI. At least 50% of all SCDs due to CHD occur as a first clinical event and among subgroups
of patients thought to be at relatively low risk for SCD [15].
SCD risk is associated with the conventional risk factors for coronary atherosclerosis [16] in‐
cluding obesity, smoking [17], genetic predisposition [18], [19], ECG pattern of LVH or
LBBB, certain angiographic parameters or heart rate profile during exercise [20].
The rhythm most  often recorded at  the time of  sudden cardiac arrest  is  VT or VF [21].
The pathophysiological mechanism underlying the arrhythmias can be variable and mul‐
tifactorial.
Transient factors may interact with a fixed substrate that, in ischemic heart disease, is attrib‐
uted to scar-based re-entry.
In chronic stage of CHD, the occurrence of SCD has an inverse relation with EF of left ven‐
tricle and, at present, this is the parameter most widely used to categorize “high risk” pa‐
tients for SCD.
Other factors that have been demonstrated to contribute to the risk for SCD after MI include
the presence of non-sustained ventricular tachycardia (nsVT), inducible VT by EP testing
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[22] or symptomatic heart failure (HF). Premature ventricular complexes (PVC) predict an
increased risk of SCD during long-term follow-up, especially if ≥ 10 PVC per hour. The pres‐
ence of frequent PVCs during or after exercise has been associated with greater risk for seri‐
ous cardiovascular events but not specifically SCD.
Several other parameters are considered predictors of sudden death, but all with low or
moderate predictive values, whose sensitivity and specificity have not yet been studied in
detail in large patient populations.
Different noninvasive exams that allow quantification of ischemia (cardiac SPECT) [23],
characterization of longitudinal strain abnormalities (echocardiography) [24] or MI scar
(Cardiac Magnetic Resonance ) [25], T wave alternant (ECG) or the presence and extent of
sympathetic denervation(cardiac 123I-MIBG imaging) were used in order to improve risk
stratification of sudden death in ischemic cardiomyopathy [26], [27].
3. Primary prevention trials
To date, seven multicenter studies were essential for defining the criteria and timing for ICD
implantation in ischemic heart disease: Multicenter Automatic Defibrillator Implantation
Trial (MADIT [28]), Coronary Artery Bypass Graft Patch (CABG-Patch) [29], Multicenter
Unsustained Tachycardia Trial (MUSTT) [30], MADIT II [31], Defibrillators In Acute Myo‐
cardial Infarction Trial (DINAMIT) [32], Sudden Cardiac Death in Heart Failure (SCD-
HeFT)8 and Immediate Risk Stratification Improves Survival (IRIS) [33].
Low LV ejection fraction (up to 30 to 40%) was the inclusion criterion similar in all of these
studies.
Specific criteria in each of the studies were the presence of non sustained ventricular tachy‐
cardia and electrophysiological study showing inducible VT (MADIT and MUSTT), recent
coronary revascularization and abnormal signal-averaged ECG (CABG-Patch), recent MI
(DINAMIT, IRIS) and heart failure (SCD-HeFT).
Based on these trials, the American College of Cardiology, American Heart Association and
the European Society of Cardiology guidelines recommend the implementation of ICDs in
all patients with an ejection fraction inferior or equal to 30%, as well as patients with EF less
than 35% with heart failure New York Heart Association (NYHA) class II or III. ICD can be
considered in postinfarction patients with EF to 40% who have sustained ventricular ar‐
rhythmias inducible during electrophysiology study [14].
As a rule, ICD implantation is not indicated in patients recovering from an acute MI (less
than 40 days) or CABG surgery (within 90 days) or in patients with NYHA class IV.
The Number needed to treat (NNT) of ICD implantation in quite different between the trials
depending on the severity of the patients evaluated and varied between 4 in MUSTT and 14
in SCD-HeFT [34].
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There is still a controversy regarding the effect of Cardiac Resynchronization Therapy (CRT)
on the risk of ventricular tachyarrhythmias, specially in patients at higher risk of heart fail‐
ure [36].Some studies suggested that epicardial activation in CRT may cause dispersion of
depolarization and prolongation of QT interval [37].
Recently, MADIT-CRT trial showed an inverse association between reverse remodeling and
the risk of subsequent ventricular tachyarrhythmias: in high responders to resynchroniza‐
tion therapy (defined as ≥25% reduction in LVESD), there was a 55% lower risk of arrhyth‐
mias at 1-year post-implantation.
It seems that reverse remodeling had a dual effect of both heart failure and arrhythmia risk
reduction [38].
4. ECG measurements
Classically, the presence of Left Bundle Branch Block (LBBB) was considered of major prog‐
nostic importance, associated with the occurrence of sudden death in patients with ischemic
heart disease. This was based on earlier studies, most of them performed before the era of
percutaneous coronary revascularization [39].
In more recent investigations, especially those resulting from secondary analyses of MUSTT
and MADIT-II trials, it has become clear that QRS prolongation is related with mortality af‐
ter MI, although the magnitude of the relationship between abnormal intraventricular con‐
duction and SCD in CHD remains unclear [40].
In an analysis of MUSTT trial, the authors noted that patients with LBBB had lower ejection
fractions and higher incidence of symptomatic heart failure, suggesting that the increase in
overall mortality was probably due to a sicker population [41].
In the MADIT-II cohort with prolonged QRS its duration (QRSd) was found to be an inde‐
pendent predictor of SCD in medically managed patients (HR 2.12) but not in ICD-treated
patients (HR 0.77).This was attributed to the fact that ICD-treated MADIT II patients died
predominantly of non-sudden HF, and QRSd would not predict HF mortality [42]
In the cardiac resynchronization therapy trial (MADIT-CRT), CRT dramatically reduces the
progression of HF in patients with a low ejection fraction and a wide QRS complex. QRS du‐
ration and morphology was considered an important prognostic factor indicating more ad‐
vanced cardiac pathology [43].
Other electrocardiographic parameters in which the prognostic value was evaluated were
T-wave  alternant  (MTWA),  the  signal-averaged  ECG  (SAECG)  and  QT  parameters  and
dynamics [44].
One of the parameters with more consistent results was MTWA. TWA consist of a fluctua‐
tion of the amplitude or morphology of the T wave every other beat assessed during exer‐
cise testing or atria pacing [45].
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A positive MTWA determined an approximately 2.5-fold higher risk of cardiac death and
life-threatening arrhythmia and showed a very high negative predictive value both in ische‐
mic [46] and no ischemic patients . According to guidelines, it is a recommendation class IIa
the use of TWA to improve the diagnosis and risk stratification of patients with ventricular
arrhythmias [14].
In a small study in patients post-MI and EF less than or equal to 30%, microvolt TWA was
better than QRS duration at identifying a high-risk group and also a low-risk group unlikely
to benefit from ICD therapy [47].
SAECG permits the identification of low-amplitude signals (microvolt level) at the end of
the QRS complex referred to as late potentials. These indicate regions of abnormal myocar‐
dium with slow conduction believed to serve as markers of the substrate for reentrant ven‐
tricular tachyarrhythmias [48]. It has a high negative predictive value but its value is lower
after coronary revascularization. [49]
5. Autonomic variables
The main variables studied included the autonomic heart rate variability (HRV)/turbulence
and the baroreceptor sensitivity.
HRV corresponds to a beat-to-beat variance in cardiac cycle length resulting from the sym‐
patho-vagal influence on the sinus node. HRV is a term that encompasses a large number of
different measures derived from 24-h Holter recordings.
In general, if such measures are extremely low, it is considered that there is autonomic dys‐
function and this has been shown to independently predict the risk of SCD in post-infarct
patients [50].
Methods based on non-linear dynamics and HR turbulence seams to provide better prog‐
nostic information than the traditional ones [51], [52].
Several studies have evaluated the prognostic value of heart rate variability in patients with
ischemic heart disease [53]. In the randomized defibrillator in AMI trial (DYNAMIT), which
used reduced SDNN combined with reduced left ventricular ejection fraction measured ear‐
ly (within 2weeks) after AMI as an inclusion criterion, there was no mortality benefit from
ICD therapy in these presumably high risk patients [32].
On the contrary, in the cardiac arrhythmias and risk stratification after myocardial infarction
(CARISMA) study, reduced HR variability measured at 6weeks after AMI, particularly the
very-low frequency spectral component, was a powerful index in predicting arrhythmic
events. The REFINE trial (Risk estimation after infarction, non-invasive evaluation) con‐
firmed that HRV and HR turbulence yield more powerful prognostic information for ar‐
rhythmic events when measured later (6–10weeks) after AMI [54].
Despite these promising results, further prospective studies are needed to determine the
usefulness of these parameters in clinical practice.
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Reduced baroreflex sensivity, a quantitative index of primarily vagal reflexes, evaluated by
the phenylephrine method or by a non-invasive measurement [55], is also useful in assess‐
ing the risk of SCD [56, 57].
6. Autonomic imaging
There is evidence that regional and global sympathetic denervation could predispose to ven‐
tricular arrhythmias in post-MI patients. The denervated but viable myocardium could be
hyperresponsive to circulating catecholamines [58, 59].
Using imaging methods for the evaluation of the sympathetic system in vivo, in human and
animal models, such as [12]3I-mIBG cardiac imaging, it has been reported that the mismatch
between sympathetic innervation and perfusion could be associated with increased risk of
ventricular arrhythmias.
The extent of sympathetic denervation measured at 4-Hour delayed 123I-mIBG SPECT imag‐
ing has been correlated with inducibility of ventricular arrhythmias in electrophysiological
testing [60]. In another study including patients with advanced heart failure, late [12]3I-
MIBG SPECT defect score was also an independent predictor for ventricular arrhythmias
causing appropriate ICD therapy (primary end point) as well as the composite of appropri‐
ate ICD therapy or cardiac death (secondary end point) [27]
More studies are required to determine the role of autonomic imaging in post-MI patients,
possibly detailing their correlation with CMR findings.
7. Electrophysiological testing
Patients after MI have the highest induction rates in electrophysiological study and the pres‐
ence of ejection fraction less than 40% and asymptomatic NSVT is associated with a induci‐
bility of 20-40% [22], [61].
Programmed ventricular stimulation identifies most patients at risk for sustained monomor‐
phic ventricular tachycardia associated with reentrant circuits that result of the healing proc‐
ess after infarction [22].
Electrophysiological study was required in MADIT, MUSTT, BEST–ICD [62], but not in
MADIT –II and SCD-HeFt trials.
Based on these trials, electrophysiological testing is not required before ICD implantation. It
is recommended (class I) for diagnostic evaluation of symptoms suggestive of tachyarrhyth‐
mias, to guide VT ablation and for differential diagnosis of a wide-QRS-complex tachycar‐
dias of unclear mechanism [14].
Electrophysiological study is also reasonable for risk stratification in patients with NSVT,
and LVEF equal or less than 40% (Class IIa). Inducibility of VT in patients with NSVT is as‐
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sociated with a high risk for VT/FV and the characteristics of NSVT could not predict the
inducibility [63].
8. Echocardiographic parameters
The echocardiogram is a fundamental exam for the identification of candidates for ICD im‐
plantation. Although an LVEF of <40% is commonly used for stratification of patients at risk
for ventricular arrhythmias, it does not allow accurate discrimination of patients with or
without sudden arrhythmic death. Moreover, sudden arrhythmic death also occurs in pa‐
tients with an LVEF of ≥40% [64].
The technical advances in echocardiography will probably allow exploring the appraisal val‐
ue of new variables beyond the ejection fraction of the left ventricle in the risk stratification.
In a unicenter study a greater involvement of peri-infarct zone longitudinal strain was inde‐
pendently associated with an increased risk of having an appropriate ICD therapy on follow-
up. In such study the odds of dying in a patient with a peri-infarct zone strain value of -6% was
approximately 11.5 times that of a patient with a peri-infarct zone strain value of -17% [65].
9. Cardiac magnetic resonance
Cardiac MRI allows characterization of cardiac morphology in patients with poor echo car‐
diographic window and provides an estimate of the location and amount of intramyocardial
fibrosis.
The presence of myocardial scar or fibrosis as measured by delayed enhancement after ad‐
ministration of gadolinium has been recently associated with post-infarct arrhythmic death
[66], [67] suggesting that contrast-enhanced MRI may enable better risk stratification for ICD
implantation among patients with prior MI compared with traditional variables such as
LVEF and NYHA class.
Roes S et al identified infarct tissue heterogeneity on contrast-enhanced MRI as a strong pre‐
dictor of spontaneous ventricular arrhythmia in ICD therapy recipients [68]. In a more re‐
cent study from a tertiary center which included the monitoring of 52 patients, it was
identified a relationship between the transmurality of infarction and the occurrence of spon‐
taneous ventricular arrhythmias in patients with chronic ischemic cardiopathy [69].
10. Conclusion
Ischemic heart disease is the heart disease in which most often there is indication for an ICD
implantation. However, after placed, these devices are used in a minority of patients in the
context of primary prevention.
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Left ventricular dysfunction remains the most robust parameter in the decision to implant
an ICD. All therapeutic measures that can accelerate or improve myocardial reperfusion by
contributing to the preservation of ventricular function are undoubtedly the best strategies
to reduce costs associated with ICDs.
In recent years numerous studies have been performed using non-invasive methods for di‐
agnosis of autonomic dysfunction or anatomic-functional abnormalities but it remains a
need for a proper validation of predictors of arrhythmic death.
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